Rein Therapeutics

(NASDAQ) ALRN

Current PriceN/A

Market CapN/A

Since IPO (2017)-99%

5 Year-95%

1 Year-28%

1 Month+0%

Rein Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

$49.87M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

ALRN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rein Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Brian J. Windsor, PhD

Website

www.reintx.com

Headquarters

Boston, MA 02210, US

ALRN Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-3%

Return on Capital

-1%

Return on Assets

-2%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$50.63M

EBITDA

$50.63M

Operating Cash Flow

$19.36M

Capital Expenditure

$0.00

Free Cash Flow

$19.36M

Cash & ST Invst.

$3.21M

Total Debt

$0.00

Rein Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$31.97M

+22.0%

EBITDA

$32.57M

+20.5%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$3.21M

-75.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-2.06%

N/A

Return on Invested Capital

-1.22%

N/A

Free Cash Flow

$3.22M

+33.1%

Operating Cash Flow

$3.22M

+33.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MGTAMagenta Therapeutics, Inc.

MGTAMagenta Therapeutics, Inc.$0.70-7.74%

GRNAGreenLight Biosciences Holdings

GRNAGreenLight Biosciences Holdings$0.30-0.03%

PSTIPluristem Therapeutics Inc.

PSTIPluristem Therapeutics Inc.$1.00-2.91%

ALVRAlloVir, Inc.

ALVRAlloVir, Inc.$9.81+4.14%

SYRESpyre Therapeutics, Inc.

SYRESpyre Therapeutics, Inc.$74.45+3.56%

BLUEbluebird bio, Inc.

BLUEbluebird bio, Inc.$4.97+0.00%

KRONKronos Bio, Inc.

KRONKronos Bio, Inc.$0.88+1.49%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$12.91+0.04%

AMZNAmazon

AMZNAmazon$265.06+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.10+0.04%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.63+0.10%

MARAMara Holdings

MARAMara Holdings$11.99+0.12%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.54+0.03%

FFord Motor Company

FFord Motor Company$12.08-0.01%

Questions About ALRN

What is the current price of Rein Therapeutics?

Rein Therapeutics is trading at N/A per share.

What is the 52-week range for Rein Therapeutics?

Over the past 52 weeks, Rein Therapeutics has traded between N/A and N/A.

How much debt does Rein Therapeutics have?

As of the most recent reporting period, Rein Therapeutics reported total debt of N/A.

How much cash does Rein Therapeutics have on hand?

Rein Therapeutics reported $3.21M in cash and cash equivalents in its most recent financial results.

What is Rein Therapeutics’s dividend yield?

Rein Therapeutics does not currently have a dividend yield.

Rein Therapeutics

Rein Therapeutics Financials at a Glance

ALRN News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Rein Therapeutics

ALRN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Rein Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ALRN

What is the current price of Rein Therapeutics?

What is the 52-week range for Rein Therapeutics?

How much debt does Rein Therapeutics have?

How much cash does Rein Therapeutics have on hand?

What is Rein Therapeutics’s dividend yield?

Premium Investing Services